Bergh T, Nillius S J, Wide L
Br Med J. 1978 Apr 8;1(6117):875-80. doi: 10.1136/bmj.1.6117.875.
Seventeen term pregnancies occurred in 14 amenorrhoeic women with hyperprolactinaemia and radiological evidence of pituitary tumour. The abortion rate was high (32%). All but one of the term pregnancies occurred after ovulation-inducing treatment with human gonadotrophins and bromocriptine (four and 12 pregnancies respectively). Two of the 14 women had visual complications during pregnancy, but neither had serious residual visual impairment. Two patients had possible pituitary enlargement during pregnancy.Bromocriptine may be the most suitable primary treatment for many infertile women with prolactin-secreting tumours. Tumour complications during pregnancy are a definite risk, but most pregnancies went uneventfully to term. Patients with pituitary tumour should be carefully evaluated before starting ovulation-inducing treatment with bromocriptine alone, and they should be told of the possible risks and of the advantages and disadvantages of pretreatment with irradiation or surgery. Patients should be carefully monitored during pregnancy and have their visual fields checked frequently. If visual complications due to tumour enlargement occur during a pregnancy, reinstituting bromocriptine may be the treatment of choice. If this fails, other forms of treatment such as induction of labour, high-dose corticosteroid treatment, pituitary implantation of yttrium-90, or surgery may be effective.
14名闭经且患有高泌乳素血症并有垂体瘤影像学证据的女性发生了17次足月妊娠。流产率很高(32%)。除1例足月妊娠外,其余均发生在使用人促性腺激素和溴隐亭诱导排卵治疗后(分别为4次和12次妊娠)。14名女性中有2名在孕期出现视力并发症,但均无严重的残余视力损害。2例患者在孕期可能出现垂体增大。溴隐亭可能是许多患有泌乳素分泌性肿瘤的不孕女性最合适的初始治疗方法。孕期肿瘤并发症确实存在风险,但大多数妊娠顺利至足月。在开始单独使用溴隐亭诱导排卵治疗前,应对垂体瘤患者进行仔细评估,并告知她们可能的风险以及放疗或手术预处理的利弊。孕期应仔细监测患者,并经常检查其视野。如果孕期因肿瘤增大出现视力并发症,重新使用溴隐亭可能是首选治疗方法。如果无效,其他治疗方法如引产、大剂量皮质类固醇治疗、垂体植入钇-90或手术可能有效。